CytRx Unveils Clinical Development Plan for Pipeline Assets

Date Posted: Thursday, December 04, 2008

Print Email to a friend

CytRx Corporation has unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term revenue potential among its clinical assets.

CytRx will pursue partnerships to advance the clinical development of INNO-406 (bafetinib) and its clinical molecular chaperone portfolio, where it continues to see significant future revenue potential.

The Company further intends to use its proprietary high-throughput, high-content drug screening Master Chaperone Regulator Assay (MaCRA) platform to discover additional molecular chaperone drug candidates, including those that may inhibit cancer growth, which will support internal efforts to build an oncology drug franchise or future out-licensing possibilities.

CytRx also announced that Board of Directors’ member Dr. Joseph Rubinfeld has accepted the additional responsibility of Chief Scientific Advisor, and will consult on all aspects of the Company’s oncology development programs while serving as an important interface between the Company and investors, clinicians and industry thought leaders.

Dr. Rubinfeld brings substantial expertise in oncology and drug development through his distinguished career. Dr. Rubinfeld was employed at Bristol-Myers Company International Division as Vice President and Director of Research and Development. While at Bristol-Myers, Dr. Rubinfeld was instrumental in licensing the original anticancer line of products, including Mitomycin and Bleomycin.

Further Information:

Related news from our archive

CytRx’s Arimoclomol to be Administered in a Phase 2/Phase 3 Adaptive Clinical Trial
The FDA funded clinical trial has commenced to study molecular chaperone regulator drug candidate in a subset of patients with familial ALS.

CytRx Reports Favorable Safety and Tolerability Results from High Dose, 28-Day Clinical Trial with Arimoclomol
Results support four-fold higher arimoclomol dose for planned Phase IIb efficacy trial for ALS.

CytRx Contributes $15 Million net to Majority-Owned RNAi Subsidiary RXi Pharmaceuticals
The contribution will satisfy RXi’s funding requirements under its agreements with the UMMS, and will increase CytRx’s ownership in RXi to nearly 90%.

CytRx RNAi Subsidiary Announces RNAi Licensing Agreement with Cold Spring Harbor Laboratory
RXi Pharmaceuticals licenses a worldwide research and therapeutic license to short hairpin RNAi technology that will allow for the triggering of RNA interference.